Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kin of IRRE-like protein 2 (KIRREL2) is a type I transmembrane glycoprotein in the immunoglobulin superfamily, primarily localized at adherens junctions in pancreatic β-cells. It is structurally related to nephrin and other NEPH proteins and contains five extracellular Ig-like domains, a transmembrane region, and a cytoplasmic tail. KIRREL2 mediates cell-cell adhesion in pancreatic islets, regulates basal insulin secretion, and undergoes regulated proteolytic processing, including extracellular shedding and γ-secretase-mediated cleavage. Its expression is largely restricted to β-cells, and autoantibodies targeting KIRREL2 are found in type 1 diabetes patients, implicating a possible role in autoimmunity. Decreased expression has been associated with glomerular disease. Four splice variants have been reported, with predominant expression in the pancreas and nervous system. Despite functional links to insulin secretion and cell-cell adhesion, there are currently no therapeutics directly targeting KIRREL2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kin of IRRE-like protein 2 (KIRREL2).